Based Therapies—Research Tools and Reagents)

4′-and 4′,4″-Substituted-3α(Diphenylmethoxy)Tropane Analogs as Cocaine Therapeutics

Newman, A.H., Allen, A.C., Kline, R.H., Izenwasser, S., Katz, J.L. (NIDA)
Filed 21 Jun 95
Serial No. 60/000,378
Licensing Contact: Leopold J. Luberecki, Jr., 301/496–7735 ext 223

The invention provides a series of 4′- and 4′,4″-substituted benztropine analogs that demonstrate high affinity binding (K_1<30nM) to the dopamine transporter and bind selectively (>100-fold) over the other monoamine transporters. These compounds block dopamine reuptake *in vitro* and yet do not demonstrate a cocaine-like behavioral profile in animal models of psychomotor stimulant abuse. Structure-Activity Relationships suggest that these compounds interact at a binding domain that differs from that of cocaine at the dopamine transporter. These compounds represent an unprecedented class of dopamine uptake inhibitors that may have potential as cocaine-abuse therapeutics, since they have neurochemical similarities to cocaine and yet do not appear to have abuse liability. Further, radiolabeled analogs will be suitable for imaging the dopamine transporter in mammalian brain using SPECT and PET and thus would be useful in the diagnoses and monitoring of neurodegenerative disorders involving the dopaminergic system (e.g., Parkinson's disease). In addition, the invention provides pharmaceutical compositions comprising an analog of the invention and a pharmaceutically acceptable carrier excipient. (portfolio: Central Nervous System—Therapeutics, psychotherapeutics, drug dependence; Central Nervous System—Therapeutics, neurological, antiparkinsonian)

Alzheimer's Disease Index (ADI)

Alkon, D.L. (NINDS)
Filed 26 Sep 95
DHHS Reference No. E–092–93/2
Licensing Contact: Stephen Finley, 301/496–7735 ext 215

Under currently available technology, Alzheimer's disease can only be presumptively diagnosed by pathological examination of brain tissue during autopsy in conjunction with a clinical history of dementia. The present invention provides a highly reliable laboratory method of identifying Alzheimer's disease in a patient. The method consists of: measuring the presence or absence of a specific potassium channel, measuring the effect of potassium channel blockers specific for the 113 pS potassium channel on intracellular calcium levels, measuring the increase of intracellular calcium in response to an activator of intracellular calcium release in the cells of a patient, and measuring the amount of the G-protein, cp20. An index calculated on the basis of any two of these four tests identifies Alzheimer's disease with very high sensitivity and specificity (n=100, initial sample) in comparisons between Alzheimer's disease patients and other non-Alzheimer's dementias as well as age-matched controls. (portfolio: Central Nervous System—Diagnostics, *in vitro*, other).

Dated: February 6, 1996.

Barbara M. McGarey,

Deputy Director, Office of Technology Transfer.

[FR Doc. 96–3184 Filed 2–12–96; 8:45 am]

BILLING CODE 4140–01–M

National Institute of Allergy and Infectious Diseases; Notice of Meeting: Chronic Fatigue Syndrome Interagency Coordinating Committee; Public Meeting

Notice is hereby given of the public meeting of the Chronic Fatigue Syndrome (CFS) Interagency Coordinating Committee, Department of Health and Human Services, on April 10, 1996 at the William H. Natcher Conference Center, Room E1/2, 45 Center Drive, Bethesda, MD.

The meeting will be open to the public from 1:00 p.m. to 4:00 p.m., on April 10, to discuss the current CFS activities and future plans of the various member agencies. It will be chaired by the Assistant Secretary for Health. During the meeting there will be an opportunity for interested persons to present information and views on issues related to CFS. Attendance by the public will be limited only by space available.

If you plan to attend the meeting, please provide your name, organization, address, telephone and FAX numbers to Dr. John La Montagne, Co-Chair, Chronic Fatigue Syndrome Interagency Coordinating Committee, Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Solar Building, Room 3A18 MSC 7630, Bethesda, MD 20892–7630. Telephone: 301–496–1884, FAX: 301–480–4528. If you also plan to make a presentation, please notify Dr. La Montagne. The time available will be allocated among the individuals who request an opportunity for a presentation (limited to five minutes). Formal written statements (five copies) may be presented to the Chair on the day of the meeting for inclusion in the minutes.

Dated: January 22, 1996.

Anthony S. Fauci,

Director, NIAID, NIH.

[FR Doc. 96–3206 Filed 2–12–96; 8:45 am]

BILLING CODE 4140–01–M

National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following National Institute of Allergy and Infectious Diseases Special Emphasis Panel (SEP) meeting:

Name of SEP: National Cooperative Drug Discovery Groups for the Treatment of Opportunistic Infection in AIDS.

Date: March 25–27, 1996.

Time: 8:30 a.m.

Place: Holiday Inn Gaithersburg, 2 Montgomery Village Avenue, Gaithersburg, MD 20879, (301) 948–8900.

Contact Person: Dr. Vassil Georgiev, Scientific Review Adm., 6003 Executive Boulevard, Solar Bldg., Room 4C04, Bethesda, MD 20892–7610, (301) 496–8206.

Purpose/Agenda: To evaluate grant applications.

The meeting will be closed in accordance with the provisions set forth in secs. 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. Applications and/or proposals and the discussions could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the applications and/or proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

(Catalog of Federal Domestic Assistance Programs Nos. 93.855, Immunology, Allergic and Immunologic Diseases Research; 93.856, Microbiology and Infectious Diseases Research, National Institutes of Health.)

Dated: February 8, 1996.

Susan K. Feldman,

Committee Management Officer, NIH.

[FR Doc. 96–3180 Filed 2–12–96; 8:45 am]

BILLING CODE 4140–01–M

National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following National Institute of Allergy and Infectious Diseases Special Emphasis Panel (SEP) meeting: